2025
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder
Ameral V, Hickey T, Reilly E, Patterson J, Sofuoglu M. Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder. Expert Opinion On Pharmacotherapy 2025, 26: 1041-1054. PMID: 40366730, PMCID: PMC12202159, DOI: 10.1080/14656566.2025.2506688.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderChronic painUse disorderCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsEffective management of painPain treatment strategiesRegister of Controlled TrialsManagement of painCochrane Central RegisterAgonist treatmentPharmacological optionsTreatment strategiesPainOpioidEffective treatmentControlled TrialsBehavioral treatmentTreatmentPatientsDisordersMedical careEffective managementEffective medical careReceipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study
Howell B, Black A, Lin H, Liberatore M, Greene C, D'Onofrio G, Heimer R, Grau L, Hawk K, Fiellin D, Becker W. Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study. Drug And Alcohol Dependence 2025, 273: 112679. PMID: 40413965, PMCID: PMC12178112, DOI: 10.1016/j.drugalcdep.2025.112679.Peer-Reviewed Original ResearchConceptsAddiction treatment modalitiesAddiction treatmentInpatient addiction treatmentOpioid overdose survivorsOverdose survivorsOpioid agonist treatmentOpioid overdoseReceipt of methadoneOpioid withdrawalInpatient treatmentBenzodiazepine exposureNon-medicalAddictionAssociated with reduced riskNonfatal opioid overdoseAgonist treatmentNon-fatal opioid overdoseTreatment modalitiesAssociated with increased riskBenzodiazepinesIndividual level dataMethadoneRetrospective cohort studyOpioidBuprenorphineGDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates
Mastaitis J, Gomez D, Raya J, Li D, Min S, Stec M, Kleiner S, McWilliams T, Altarejos J, Murphy A, Yancopoulos G, Sleeman M. GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications 2025, 16: 4377. PMID: 40360507, PMCID: PMC12075787, DOI: 10.1038/s41467-025-59485-9.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsReceptor agonistsA blockadeGlucagon-like peptide-1 receptor agonist treatmentMuscle lossMuscle massFat lossObese male miceNon-human primatesType II activin receptorTreatment of obesityQuality of weight lossSignificant muscle lossIncrease muscle massEnhanced fat lossAgonist treatmentMale miceMuscle preservationAppetite suppressionActivin AActivin receptorsObese miceCaloric restrictionWeight loss
2023
Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
Bromberg D, Galvez de Leon S, Litz T, Azbel L, Liberman A, Polonsky M, Dvoriak S, Saichuk N, Taxman F, Altice F. Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment. PLOS Global Public Health 2023, 3: e0002349. PMID: 37910486, PMCID: PMC10619786, DOI: 10.1371/journal.pgph.0002349.Peer-Reviewed Original ResearchCriminal justice settingsOpioid use disorderBrief interventionUse disordersPrevalence of OUDProbation centersHIV prevention effortsJustice settingsMental healthHigh rateCommunity supervision settingsOAT servicesSBIRT interventionAgonist therapyHIV testingOpioid dependenceAgonist treatmentConsecutive individualsTreatment strategiesGeneral populationProbationSBIRTPrevention effortsSupervision settingParticipantsEconomic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross J, Marsh E, Weitz M, Savinkina A, Schackman B, Wang J, Madushani R, Morgan J, Barocas J, Walley A, Chrysanthopoulou S, Linas B, Assoumou S. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Network Open 2023, 6: e2329583. PMID: 37703018, PMCID: PMC10500382, DOI: 10.1001/jamanetworkopen.2023.29583.Peer-Reviewed Original ResearchConceptsExtended-release buprenorphineIncremental cost-effectiveness ratioMedication treatmentHealth care utilization costsTreatment of OUDOpioid agonist treatmentOpioid use disorderMean lifetime costsCost-effectiveness ratioProbabilistic sensitivity analysesEconomic evaluationCohort studyAgonist treatmentTreatment optionsClinical trialsClosed cohortMAIN OUTCOMEBuprenorphineSimulated cohortUse disordersDrug AdministrationUS FoodPharmaceutical costsQALY willingnessInjectable formPrevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis
Aghaei A, Gholami J, Sangchooli A, Rostam-Abadi Y, Olamazadeh S, Ardeshir M, Baheshmat S, Shadloo B, Taj M, Saeed K, Rahimi-Movaghar A. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. The Lancet Global Health 2023, 11: e1225-e1237. PMID: 37474230, DOI: 10.1016/s2214-109x(23)00267-x.Peer-Reviewed Original ResearchConceptsPrevalence of injection drug useInjection drug usePrevalence of HIVHepatitis B virusHepatitis C virusB virusC virusMeta-analysisSystematic reviewHepatitis C virus infection ratesEastern Mediterranean RegionCharacteristics of peopleDrug useHIV infection ratesOpioid agonist treatmentInfection rateProgramme servicesPopulation size of peopleHepatitis CAgonist treatmentHarm reduction servicesHepatitis BWHO Eastern Mediterranean RegionWeb of ScienceProvision of servicesASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
Weimer M, Herring A, Kawasaki S, Meyer M, Kleykamp B, Ramsey K. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. Journal Of Addiction Medicine 2023, 17: 632-639. PMID: 37934520, DOI: 10.1097/adm.0000000000001202.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh potency synthetic opioidsOpioid use disorderBuprenorphine initiationBuprenorphine treatmentTreatment needsUse disordersClinical considerationsExpert consensusSynthetic opioidsTreatment of OUDProspective researchOpioid agonist treatmentLong-term treatmentDrug supplyPatients' treatment needsOpioid withdrawalBuprenorphine doseOUD treatmentAgonist treatmentDosing frequencyClinical questionsFrontline cliniciansClinical practiceTreatment settingsIndividualized strategiesModelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine
Stone J, Trickey A, Walker J, Bivegete S, Semchuk N, Sazonova Y, Varetska O, Altice F, Saliuk T, Vickerman P. Modelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine. Journal Of The International AIDS Society 2023, 26: e26073. PMID: 37012669, PMCID: PMC10070931, DOI: 10.1002/jia2.26073.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHepatitis C virusHCV incidenceHCV infectionHIV/HCV testingHIV/HCV infectionHCV transmission modelNeedles/syringesHCV testingHCV eliminationHCV transmissionAgonist treatmentC virusNew HIVHigh prevalencePWIDHIVCondom useSubstantial detrimental impactInfectionIncidencePreventative impactDrugsCoverage levelsDALYsDrug use, drug use disorders, and treatment services in the Eastern Mediterranean region: a systematic review
Rostam-Abadi Y, Gholami J, Jobehdar M, Ardeshir M, Aghaei A, Olamazadeh S, Taj M, Saeed K, Mojtabai R, Rahimi-Movaghar A. Drug use, drug use disorders, and treatment services in the Eastern Mediterranean region: a systematic review. The Lancet Psychiatry 2023, 10: 282-295. PMID: 36848914, DOI: 10.1016/s2215-0366(22)00435-7.Peer-Reviewed Original ResearchConceptsDrug use disordersEastern Mediterranean RegionDrug useTreatment servicesUse disorderIncreasing global public health concernCost-effective carePrevalence of drug use disordersGlobal public health concernPublic health concernPrevalence of drug useGrey literaturePatterns of drug useOpioid agonist treatmentEvidence-basedSystematic reviewTreatment coverageHealth concernAgonist treatmentRegional levelYoung peoplePrevalenceOnline databasesDrugLimited dataIncreased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy
Rupert C, López J, Cortez-Toledo E, De la Cruz Cabrera O, Chesler N, Simpson P, Campbell S, Baker A. Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy. AJP Heart And Circulatory Physiology 2023, 324: h293-h304. PMID: 36637971, PMCID: PMC9886349, DOI: 10.1152/ajpheart.00279.2022.Peer-Reviewed Original ResearchConceptsHuman heart failureHeart failureAR stimulationChronic stimulationLength-dependent activationVehicle treatmentHeart tissueAdrenergic receptorsHuman EHTsAnimal heart failure modelNovel heart failure therapiesHeart failure therapyHeart failure modelMultiple preclinical modelsFailure therapyAgonist treatmentSeparate control experimentsPreclinical modelsDrug washoutTherapeutic effectTranslational significanceHuman myocardiumBaseline testingRNA-seq analysisPig myocardium
2022
Childhood Adversity, Addiction Severity, and Comorbidity Among Patients Receiving Opioid Use Disorder Treatment
Carr M, Ellis J, Saules K, Ledgerwood D. Childhood Adversity, Addiction Severity, and Comorbidity Among Patients Receiving Opioid Use Disorder Treatment. The Journal Of Nervous And Mental Disease 2022, 211: 150-156. PMID: 36112518, DOI: 10.1097/nmd.0000000000001581.Peer-Reviewed Original ResearchConceptsOpioid use disorder treatmentUse disorder treatmentClinical severityChildhood adversityDisorder treatmentOpioid agonist treatmentChildhood adversity exposureGreater childhood adversityOUD treatmentAgonist treatmentTreatment strategiesEmotion dysregulationEmotion regulationCurrent psychopathologyAddiction severityPatientsAdversity exposureSymptom typeSeverityWomenStrongest predictorTreatmentHigh rateDysregulationGreater exposureHealth-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal Of Addictive Diseases 2022, 41: 213-224. PMID: 35920743, DOI: 10.1080/10550887.2022.2088978.Peer-Reviewed Original ResearchConceptsElbasvir/grazoprevirHepatitis C virus infectionC virus infectionOpioid agonist therapyHealth-related qualityEnd of treatmentHCV infectionAgonist therapyVirus infectionChronic hepatitis C virus (HCV) infectionImproved health-related qualityMental component summary scoresTreatment week 4Placebo-controlled studyOpioid agonist treatmentMedical Outcomes StudyComponent summary scoresSF-36v2 scoresTreatment differencesImproved HRQOLViral eradicationActing antiviralsOpioid dependenceAgonist treatmentGeneral health
2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisordersModelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, Rahimi-Movaghar A, Alavi M, Young AM, Havens JR, Miller WC, Hickman M, Vickerman P. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. The Lancet Psychiatry 2021, 8: 301-309. PMID: 33640039, PMCID: PMC8255389, DOI: 10.1016/s2215-0366(20)30538-1.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentDrug-related deathsOAT coverageDrug-related harmAgonist treatmentHepatitis C virus transmissionC virus transmissionOverall health benefitsUK National InstituteNational InstituteHIV 0OAT retentionHIV mortalityInjury 3Opioid dependenceMortality outcomesUS National InstitutesHCV-2Overdose deathsSignificant additional effectIntervention effectsDrug abuseHealth benefitsMortalityDeathThe Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes
MacLean R, Spinola S, Garcia-Vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Current Addiction Reports 2021, 8: 100-108. DOI: 10.1007/s40429-020-00352-6.Peer-Reviewed Original ResearchOpioid agonist treatmentChronic painOpioid use disorderOpioid Use Disorder Treatment OutcomesNonpharmacologic pain treatmentsIllicit opioid useDisorder treatment outcomesReviewChronic painOpioid usePain intensityPain treatmentAgonist treatmentOAT clinicsTreatment outcomesClinical carePainUse disordersDrug useRecent FindingsWeHigher likelihoodClinicOutcomesTreatmentMost studiesIntake
2020
Therapies Offered at Residential Addiction Treatment Programs in the United States
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies Offered at Residential Addiction Treatment Programs in the United States. JAMA 2020, 324: 804-806. PMID: 32840587, PMCID: PMC7448823, DOI: 10.1001/jama.2020.8969.Peer-Reviewed Original ResearchConceptsResidential addiction treatment programOpioid agonist treatmentResidential addiction treatment facilityOpioid use disorderAddiction treatment facilitiesAddiction treatment programsNonpharmacologic therapiesAgonist treatmentPatient callsUse disordersTreatment programCenter statusTherapyRandom sampleCo-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatmentGlobal opioid agonist treatment: a review of clinical practices by country
Jin H, Marshall B, Degenhardt L, Strang J, Hickman M, Fiellin D, Ali R, Bruneau J, Larney S. Global opioid agonist treatment: a review of clinical practices by country. Addiction 2020, 115: 2243-2254. PMID: 32289189, PMCID: PMC7554123, DOI: 10.1111/add.15087.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderUrine drug screeningRoutine clinical practiceClinical practiceUnsupervised dosingUse disordersObservational cohort studySignificant clinical benefitSearch of PubMedGrey literature databasesCohort studyMedian dosesOpioid dependenceAgonist treatmentClinical benefitPrescribing practicesEligible studiesOAT programsScreening practicesEligibility criteriaBuprenorphineMethadoneTreatment practicesLiterature databasesInitiating Opioid Agonist Treatment for Opioid use Disorder Nationally in the Veterans Health Administration: Who Gets What?
Manhapra A, Stefanovics E, Rosenheck R. Initiating Opioid Agonist Treatment for Opioid use Disorder Nationally in the Veterans Health Administration: Who Gets What? Substance Abuse 2020, 41: 110-120. PMID: 31403914, DOI: 10.1080/08897077.2019.1640831.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderMethadone maintenance treatmentUse disordersOAT initiationAgonist treatmentHigher oddsMultivariate logistic regression modelVeterans Health AdministrationNational administrative dataDrug use variablesLogistic regression modelsMMT initiationPatient characteristicsIndependent predictorsMaintenance treatmentBlack raceFiscal year 2012Inpatient treatmentLower oddsBuprenorphineHealth AdministrationOpioid crisisSociodemographic characteristicsPatients
2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply